Raffaele Campisi
Overview
Explore the profile of Raffaele Campisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calabrese C, Nolasco S, Annunziata A, Sola A, Imitazione P, Campisi R, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458096
: High-flow nasal therapy (HFNT) has been shown to reduce exacerbations of COPD and some evidence displays benefits in non-cystic fibrosis bronchiectasis (NCFB) patients. The present study aimed to compare...
2.
Di Bona D, Bilancia M, Crimi C, Daddato M, Benfante A, Caiaffa M, et al.
Clin Exp Allergy
. 2024 Oct;
55(2):202-204.
PMID: 39390847
This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin...
3.
Campisi R, Nolasco S, Mancuso M, Spinella M, Vignera F, Crimi N, et al.
J Clin Med
. 2024 Aug;
13(16).
PMID: 39201075
Bronchiectasis (BE) has been traditionally associated with neutrophilic inflammation, but eosinophilic bronchiectasis (EB) has recently emerged. Data about prevalence, clinical features, and disease severity are lacking. This study aimed to...
4.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta V, Di Bona D, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(12):3315-3327.
PMID: 39197750
Background: Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. Although mepolizumab's short-term effectiveness is established, there is limited evidence on its ability to achieve long-term...
5.
Pelaia C, Crimi C, Benfante A, Caiaffa M, Campisi R, Candia C, et al.
Respirology
. 2024 Jun;
29(10):869-879.
PMID: 38847185
Background And Objective: Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission...
6.
Chessari C, Simonetta E, Amati F, Nigro M, Stainer A, Sotgiu G, et al.
ERJ Open Res
. 2024 Mar;
10(2).
PMID: 38500794
https://bit.ly/46XMWAz.
7.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, et al.
ERJ Open Res
. 2023 Nov;
9(5).
PMID: 37908397
Background: The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated...
8.
Nolasco S, Crimi C, Campisi R
J Pers Med
. 2023 Oct;
13(10).
PMID: 37888070
Asthma is one of the most common chronic respiratory diseases, affecting over 300 million people worldwide [...].
9.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, et al.
Front Immunol
. 2023 Jul;
14:1204444.
PMID: 37457743
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia. Objective: To assess the effectiveness and safety of mepolizumab (anti-IL-5)...
10.
Campisi R, Nolasco S, Pelaia C, Impellizzeri P, DAmato M, Portacci A, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373648
: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking....